Pfizer (NYSE:PFE) Trading Up 1.4% on Strong Earnings

Pfizer Inc. (NYSE:PFE)’s stock price shot up 1.4% during trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $25.81 and last traded at $25.7640. 46,896,969 shares traded hands during trading, an increase of 11% from the average session volume of 42,334,035 shares. The stock had previously closed at $25.41.

The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the business earned $0.78 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported adjusted earnings of $0.77 per share and revenue of $15.03 billion, exceeding analyst estimates of $0.68 and $14.40 billion, respectively. Eliquis, oncology products and recently launched or acquired medicines drove growth. Reuters: Pfizer beats quarterly profit estimates
• Positive Sentiment: The company raised its 2026 revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, lifting the midpoint by $500 million while reaffirming adjusted EPS guidance of $2.80-$3.00. CNBC: Pfizer tops quarterly estimates
• Positive Sentiment: Management highlighted an additional $2.5 billion cost-reduction target by 2029, which could support margins and help offset patent expirations and weaker pandemic-product demand. Economic Times: Pfizer targets additional cost cuts
• Positive Sentiment: Pfizer also reported positive Phase 3 data for LITFULO in vitiligo, adding a potential pipeline catalyst as investors assess the company’s post-COVID growth prospects. Pfizer reports positive Phase 3 LITFULO data
• Neutral Sentiment: The earnings call emphasized that non-COVID products are becoming the primary recovery engine, with management also pointing to oncology expansion and obesity-drug development as longer-term opportunities. Pfizer Q2 earnings call highlights
• Negative Sentiment: COVID product revenue remains under pressure, and the company’s GAAP quarterly loss and EPS outlook midpoint below consensus may limit enthusiasm despite the operational beat. Pfizer faces continued COVID fallout

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $28.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PFE. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. United Bank boosted its stake in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Pfizer by 31.5% during the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC grew its holdings in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.4%

The business has a 50-day moving average price of $25.02 and a 200-day moving average price of $26.16. The company has a market capitalization of $146.84 billion, a price-to-earnings ratio of 19.67 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.